The USPTO has announced the COVID-19 Prioritized Examination Pilot Program to incentivize prompt research into treatment of this pandemic. The program will benefit small and micro entities by allowing them to file for prioritized examination without the typical fees. To qualify for this program, the claims of the application must cover a product or process that is subject to FDA approval for use in the prevention and/or treatment of COVID-19. The USPTO aims to reach final disposition of applications to this program within six months, if the applicant responds promptly to USPTO communications. WHIPgroup attorneys have significant experience in products and processes subject to FDA approval, including medical devices and chemical compositions. We are ready and able to help you take advantage of this program.
Under U.S. law, anyone who uses a system that is likely to have been made by a patented process, and who does not demonstrate that the system was not made by the patented process, is [Read More…]
Recently, WHIPGROUP engaged in an arbitration that included a five day hearing in the City. Here are some thoughts about why arbitration is different (not clearly better or worse) than litigation. Venue The AAA arbitral [Read More…]
WHIPGroup previously filed a Motion to Dismiss a patent infringement suit filed against its client TomTom in the Western District of Texas. Rather than opposing WHIPGroup’s motion to dismiss, Plaintiff MDSP Technologies LLC voluntarily dismissed [Read More…]